Clinical Trial Update: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating Teclistamab in combination with Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in combination with Daratumumab a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Revlimid (lenalidomide)
• TECVAYLI (TECLISTAMAB-CQYV)
• Talquetamab (talquetamab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING